The detection of rheumatoid arthritis a chronic autoimmune disorder, relies on early diagnosis to manage symptoms and slow disease progression effectively. Among the most specific biomarkers for RA are anti-cyclic citrullinated peptide antibodies, which often appear in the bloodstream long before clinical symptoms manifest. Conventional laboratory-based diagnostic methods, while effective, are time-consuming, require specialized facilities, and are inaccessible to many patients in low-resource settings. To address these limitations, rapid microfluidic biosensors have emerged as a promising solution for point-of-care detection of RA through the analysis of anti-CCP antibodies. These biosensors combine the principles of microfluidics and advanced bio-detection techniques, offering a fast, portable, and highly sensitive alternative for early diagnosis. Microfluidic biosensors are devices that utilize microchannels to manipulate small volumes of fluids, enabling the precise control and analysis of biological samples. By miniaturizing diagnostic processes, these devices achieve remarkable speed and efficiency while reducing reagent and sample consumption. For detecting anti-CCP antibodies, microfluidic biosensors are designed with functionalized surfaces that bind specifically to these biomarkers. The specificity of this interaction ensures accurate detection, even in complex biological matrices such as blood, serum, or synovial fluid.
HTML PDFShare this article
Biosensors & Bioelectronics received 6207 citations as per Google Scholar report
